Table 5 Mean AUC values for capecitabine, 5-FU and its metabolites

From: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

 

AUC (0–12 h) (s.d.) (mg ml −1  h)

 

Capecitabine

5-FU

5′-DFCR

5′-DFUR

Capecitabine twice daily dose (mg m−2)

Cycle 1

Cycle 2

Cycle 1

Cycle 2

Cycle 1

Cycle 2

Cycle 1

Cycle 2

700

3652 (1234)

3208 (820)

555 (157)

322 (130)

1929 N/A

2087 (910)

13 495 (4335)

11 179 (1300)

850

4343 (793)

4248 (1156)

407 (70)

465 (210)

1286 (586)

1890 (1164)

11 916 (1518)

10 887 (1914)

1000

7700 (3046)

7322 (3620)

478 (172)

598 (326)

6149 (3818)

7285 (3610)

14 341 (6769)

15 836 (3048)

1150

11 553 (5814)

11 188 (7377)

621 (156)

516 (189)

9967 (3526)

11 110 (2520)

18 001 (2572)

16 289 (5383)

  1. AUC=area under the curve; s.d.=standard deviation; 5-FU=5-fluorouracil; DFCR=5′-deoxy-5-fluorocytidine; DFUR=5′-deoxy-5-fluorouridine; N/A=not available.